Tagged with BI

Pharma Legal Handbook Read more to find out about patents and trademarks in Colombian pharma. Prepared in association with Cavelier Abogados, a leading global law firm, this is an extract from The Pharma Legal Handbook: Colombia, available to purchase here for GBP 119.   1. What are the basic requirements to obtain patent and…

Pharma Legal Handbook Regulatory reforms in Colombia – a legal guide. Prepared in association with Cavelier Abogados, a leading global law firm, this is an extract from The Pharma Legal Handbook: Colombia, available to purchase here for GBP 119.   1. Are there proposals for reform or significant change to the healthcare system? Yes,…

Pharma Legal Handbook All legal aspects surrounding cannabinoid drugs, medicinal cannabis and opioid drugs in Colombia. Prepared in association with Cavelier Abogados, a leading law firm in Colombia, this is an extract from The Pharma Legal Handbook: Colombia, available to purchase here for GBP 119. Cannabinoid Drugs 1. Are Cannabinoid Drugs authorized in…

Pharma Legal Handbook The key facts about biosimilars and biologics in Colombia. Prepared in association with Cavelier Abogados, a leading global law firm, this is an extract from The Pharma Legal Handbook: Colombia, available to purchase here for GBP 119.   1. Are biosimilar medicines considered the same as generic medicines in your country?…

India The latest news from the Indian pharma sector, including the potential for greater numbers of exports and better market access to the UK under a proposed free trade agreement, yet another scandal – this time over contaminated cough syrup in Gambia –, and why 200 million doses of Bharat Biotech’s…

South Korea After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already securely anchored in the American life sciences ecosystem: former senior program officer in global health at the Bill & Melinda…

Canada Drs Neil Cashman and Larry Altstiel of ProMIS Neurosciences weigh in on recent progress towards an effective therapy for Alzheimer’s disease, potentially representing a break from three decades of scientific stagnation.   Are we there yet with Alzheimer’s immunotherapies? No. But we have a map, and it’s a good one.…

UK With the brief tenure of Liz Truss as Prime Minister already drawing to a close, the UK faces yet another new leader as the country attempts to extricate itself from the financial havoc wreaked by the Truss administration. Despite this backdrop, activity continues in the UK’s vibrant healthcare and life…

China A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR deal with SciClone Pharmaceuticals.   Moderna holds onto its vaccine IP and refuses tech transfer in China (Financial Times) Moderna…

Canada Biosimilar uptake initiatives are gaining traction across Canada and have already been implemented in several provinces. Dara Jospé and Lina Bensaidane of Fasken examine the impact of these policies on patients, prescribers, and pharmacists thus far, and the implications should non-medical biosimilar switching become a nationwide norm.   In the…

Global The FDA’s recent accelerated approval for Bluebird Bio’s gene therapy Skysona and its US list price of USD three million per treatment has reignited the global debate around drug pricing. Bluebird execs are keen to emphasise how life-changing such treatments are for a small number of patients; Skysona is indicated…

Spain Over the course of 2022, PharmaBoardroom spoke to over 50 leading stakeholders in the Spanish healthcare and life sciences, from top Spanish scientists to regional ministers of health, multinational affiliate managers, and the heads of some of the country’s leading domestic firms. These interviewees’ insights are catalogued in the downloadable…